Physiomics (GB:PYC) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Physiomics PLC, a mathematical modelling and data science company, has secured a £186k contract with a major client to provide cancer drug development support using its Virtual Tumour platform. This agreement, which is set to be completed within the current year, propels Physiomics into the next fiscal year with over £0.5m in committed revenues. The company’s expertise in complex therapy modelling has been instrumental in clinching this deal, showcasing its valuable role in the pharmaceutical industry.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
